The anti-cancer efficacy of pyrimethamine on non-small cell lung cancer

• Main Authors: Min-Hsuan Lin, 林湣萱
• Other Authors: CHI-CHEN LIN
• Format: Others
• Language: zh-TW
• Published: 2016
• Online Access: http://ndltd.ncl.edu.tw/handle/39657328237934340321

碩士 === 國立中興大學 === 生命科學院碩士在職專班 === 104 === Despite several studies had reported the anti-tumor effect of Pyrimethamine (PYR) in vitro and in vivo in many tumors, there is none about non-small cell lung cancer (NSCLC). In this study, we demonstrated that PYR reduces the cell viability of NSCLC cell lines A549 and induces G1 phase arrest in cells. Double staining of Annexin V and PI indicated that PYR could induce apoptosis in A549 cell, PYR induces sub-G1 phase accumulation. Furthermore, PYR can also induce the pro-survival autophagy in A549 cells. These results suggested PYR induces G1 phase arrest apoptosis to affect the proliferation of A549 cells. PYR also induces the pro-survival autophagy to maintain A549 survival. In summary, our findings showed that PYR promotes intrinsic apoptosis by inducing apoptotic protein activation and can also induces autophagy, suggesting PYR may be considered as chemo-prevention or treatment NSCLC.